First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...

Related Keywords

United States ,Russia ,Ukraine ,Efthymiosn Deliargyris ,Eric Kim ,Apixaban Eliquis ,Janssen Bayer ,Twitter ,Material Command ,European Union ,Expenditure Panel ,Facebook ,Us Army ,Blood Institute ,Cytosorbents Corporation ,National Heart ,National Institutes Of Health ,Human Services ,Us Department Of Health ,Us Air ,Corporate Communications ,Agency For Healthcare Research ,Chief Medical Officer ,Cytosorbents Breakthrough Device Designation ,Direct Oral Anticoagulants ,Sorbents Corporation ,Use Authorization ,Removal System ,Timely Antithrombotic Removal Ticagrelor ,Timely Antithrombotic Removal ,Oral Anticoagulants ,National Institutes ,Operations Command ,Air Force Material Command ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Relations Contact ,Healthcare Research ,Medical Expenditure Panel ,